- NCIt
- C5028
Loading cancer entity…
Loading cancer entity…
Clinical trials
110 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07637734 | Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)(COVE-3) | recruiting | Phase 3 | 300 | Verrica Pharmaceuticals Inc.INDUSTRY | 2 | Sep 3, 2026 | clinicaltrials |
| NCT04635423 | Efficacy, Immunogenicity, and Safety Study of V503 (9-valent Human Papillomavirus [9vHPV] Vaccine) in Japanese Males (V503-064) | completed | Phase 3 | 1,059 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jun 11, 2026 |
| clinicaltrials |
| NCT07457918 | Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)(COVE-4) | recruiting | Phase 3 | 600 | Verrica Pharmaceuticals Inc.INDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT05937672 | Cold Atmospheric Plasma Device Extension Study | terminated | Phase 3 | 60 | Medical University of South CarolinaOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT02750202 | Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts(TheraVACCS) | completed | Phase 3 | 52 | University of PretoriaOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07246590 | Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)(COVE-2) | recruiting | Phase 3 | 300 | Verrica Pharmaceuticals Inc.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05889845 | Candin for the Treatment of Common Warts | completed | Phase 3 | 330 | Nielsen BioSciences, Inc.INDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT00092534 | Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)(FUTURE II) | completed | Phase 3 | 12,167 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 1, 2025 | clinicaltrials |
| NCT06866574 | A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males | active not recruiting | Phase 3 | 9,300 | Xiamen UniversityOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT06465914 | A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males | active not recruiting | Phase 3 | 9,000 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT04422366 | Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | recruiting | Phase 3 | 8,000 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Jun 7, 2024 | clinicaltrials |
| NCT04895020 | Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years | unknown | Phase 3 | 1,200 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05027776 | Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years | recruiting | Phase 3 | 1,348 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05372016 | Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | completed | Phase 3 | 1,200 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05584332 | A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females | terminated | Phase 3 | 3,131 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Jul 21, 2023 | clinicaltrials |
| NCT05314023 | Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053) | active not recruiting | Phase 3 | 1,590 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jan 19, 2023 | clinicaltrials |
| NCT05580341 | Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9 | unknown | Phase 3 | 1,200 | Shanghai Zerun Biotechnology Co.,LtdINDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT04425291 | Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | completed | Phase 3 | 1,680 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Feb 25, 2022 | clinicaltrials |
| NCT03812510 | Safety Study of A-101 Topical Solution for the Treatment of Common Warts | completed | Phase 3 | 426 | Aclaris Therapeutics, Inc.INDUSTRY | 1 | Nov 23, 2020 | clinicaltrials |
| NCT03691831 | A Study of A-101 Topical Solution for the Treatment of Common Warts | completed | Phase 3 | 502 | Aclaris Therapeutics, Inc.INDUSTRY | 1 | Oct 27, 2020 | clinicaltrials |
| NCT03687372 | Study of A-101 Topical Solution for the Treatment of Common Warts | completed | Phase 3 | 503 | Aclaris Therapeutics, Inc.INDUSTRY | 1 | Oct 5, 2020 | clinicaltrials |
| NCT04288817 | Efficacy of Cryotherapy Combined With Intralesional Tuberculin PPD Versus Intralesional Tuberculin PPD in Treatment of Multiple Common Warts | unknown | Phase 3 | 40 | Assiut UniversityOTHER | 0 | Feb 28, 2020 | clinicaltrials |
| NCT03158220 | Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) | completed | Phase 3 | 1,212 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Nov 21, 2019 | clinicaltrials |
| NCT00543543 | Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) | completed | Phase 3 | 14,840 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 27, 2018 | clinicaltrials |
| NCT01047345 | A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) | completed | Phase 3 | 924 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 27, 2018 | clinicaltrials |
| NCT01651949 | Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003) | completed | Phase 3 | 2,520 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 27, 2018 | clinicaltrials |
| NCT03296397 | Efficacy of Quadrivalent HPV Vaccine to Prevent Relapses of Genital Warts After Initial Therapeutic Response(CONDYVAC) | unknown | Phase 3 | 300 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Feb 27, 2018 | clinicaltrials |
| NCT03153566 | Comparison Between Tuberculin Vaccine and Cryotherapy in Genital Wart Patients | unknown | Phase 3 | 45 | Assiut UniversityOTHER | 0 | May 17, 2017 | clinicaltrials |
| NCT00092482 | Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED) | completed | Phase 3 | 3,882 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 22, 2017 | clinicaltrials |
| NCT00517309 | Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED)(FUTURE) | completed | Phase 3 | 1,877 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 22, 2017 | clinicaltrials |
| NCT00092521 | Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) | completed | Phase 3 | 5,759 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 25, 2015 | clinicaltrials |
| NCT00501137 | A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine(BCGov-01) | completed | Phase 3 | 830 | Simon DobsonOTHER | 1 | Apr 10, 2015 | clinicaltrials |
| NCT01639638 | Recurrent and Nonrecurrent Condyloma Treatment | terminated | Phase 2 / Phase 3 | 132 | Laboratorio Elea Phoenix S.A.INDUSTRY | 1 | Mar 12, 2015 | clinicaltrials |
| NCT00092495 | Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016) | completed | Phase 3 | 3,055 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 13, 2015 | clinicaltrials |
| NCT02151630 | Pyruvic Acid Versus Salicylic Acid Preparation in Treatment of Plantar Warts | unknown | Phase 2 / Phase 3 | 60 | Isfahan University of Medical SciencesOTHER | 1 | May 30, 2014 | clinicaltrials |
| NCT00735462 | Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts | completed | Phase 3 | 511 | Graceway Pharmaceuticals, LLCINDUSTRY | 1 | Jul 20, 2011 | clinicaltrials |
| NCT00674739 | Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts | completed | Phase 3 | 470 | Graceway Pharmaceuticals, LLCINDUSTRY | 1 | May 24, 2011 | clinicaltrials |
| NCT00999986 | Low Dose Cyclophosphamide Treats Genital Warts | completed | Phase 3 | 104 | Huazhong University of Science and TechnologyOTHER | 1 | Nov 25, 2009 | clinicaltrials |
Data updated 22 days agoSource updated Sep 3, 2026source: clinicaltrials